Oxford Biomedica
OXB · Main Market · Health Care · mcap £631m · 535.0p
Answered by AI only from OXB’s own announcements and the figures in its results, every statement linked to its source. Free with an account – no password, just a link. Not investment advice.
- Market cap
- £648m
- EV
- £626m
- Net cash
- £21.4m
- Revenue
- £175m
- Operating profit
- −£28.0m
- Shares
- 121.0m +0.5%
| FY24 | FY25 | |
|---|---|---|
| Shares m | 106.0 | 120.5 |
| Change | +13.8% |
Count in force at each financial year end (excl. treasury shares), from the company's voting rights notices or its results. Red: dilution above 5% a year; green: share count falling. * adjusted for a consolidation or split.
-
2 Oct
Grant of Award
Oxford, UK – 02 October 2026: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, announces that on 30 September 2026, nil-cost share...
-
22 Sep
Half-year Results
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026
-
7 Aug
Half Year Trading Update and Notice of Results
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No.
-
16 Jul
Manufacturing agreement with Plowshare Therapies
OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies' AAV Gene Therapy Programme
-
2 Jun
OXB Capital Markets Event
· OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy market
Company filings. Not investment advice.